In October 2014, the White House paused funding for gain-of-function research on influenza, SARS, and MERS viruses to assess risks and benefits. The National Science Advisory Board for Biosecurity tasked Gryphon Scientific with conducting comprehensive risk and benefit assessments covering biosafety, laboratory security, information misuse, and research benefits.